AZABICYCLIC COMPOUNDS AS SEROTONINE, DOPAMINE AND NOREPINEPHRINE RE-UPTAKE INHIBITORS

摘要

The present invention relates to novel compounds of Formula (I)' or pharmaceutically acceptable salts or a solvates thereof: wherein A is and K is a mono or bicyclic aryl group; R<SUB>1</SUB> is selected from a group consisting of: halogen, C<SUB>1-4</SUB>alkyl and C<SUB>1-4</SUB>alkoxy, and such R<SUB>1</SUB> may assume different meanings on the basis of p value; p is an integer from 0 to 5; R<SUB>2</SUB> is a group P wherein P is and R<SUB>3</SUB> is hydrogen, C<SUB>1-4</SUB>alkyl, C<SUB>3-6</SUB>cycloalkyl, C<SUB>3-6</SUB>cycloalkylC<SUB>1-3</SUB>alkyl, haloC<SUB>1-2</SUB>alkyl or an optionally substituted phenyl group; X is oxygen, -NR<SUB>8</SUB>- or sulphur; n is 0 or 1; R<SUB>7</SUB> is hydrogen or methyl; R<SUB>4</SUB> is hydrogen or methyl; R<SUB>5</SUB> is hydrogen or C<SUB>1-4</SUB>alkyl; R<SUB>6</SUB> is hydrogen or C<SUB>1-4</SUB>alkyl; and R<SUB>8</SUB> is hydrogen or C<SUB>1-4</SUB>alkyl; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as serotonin (5-HT), dopamine (DA) and norepinephrine (NE), re-uptake inhibitors.